Search Within

Sarat Chandarlapaty

Formats
  1. Meeting Abstract (143)
  2. Journal Article (127)
  3. Review (9)
  4. Editorial (3)
  5. Guidelines (2)
  6. Book Section (1)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (285)
  2. Breast Medicine Service (285)
  3. Department of Medicine (285)
  4. GSK Faculty (285)
  5. Human Oncology and Pathogenesis Program (285)
  6. Solid Tumor Oncology Division (285)

More Groups

People
  1. Pedram Razavi (79)
  2. Jorge Reis-Filho (65)
  3. Neal Rosen (57)
  4. Shanu Modi (51)
  5. Jose Baselga (48)
  6. Britta Weigelt (43)

More People

Years
  1. 2025 (15)
  2. 2024 (30)
  3. 2023 (17)
  4. 2022 (25)
  5. 2021 (23)
  6. 2020 (33)

More Years

Publications
  1. Cancer Research (65)
  2. Journal of Clinical Oncology (53)
  3. Annals of Oncology (21)
  4. Cancer Discovery (11)
  5. Clinical Cancer Research (11)
  6. Laboratory Investigation (11)

More Publications

Publishers
  1. American Association for Cancer Research (90)
  2. American Society of Clinical Oncology (57)
  3. Nature Publishing Group (38)
  4. Oxford University Press (24)
  5. Cell Press (14)
  6. Elsevier Inc. (11)

More Publishers

Results (285)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Management of patients with advanced-stage HER2-positive breast cancer: Current evidence and future perspectives
    Review

    Marra, A.; Chandarlapaty, S.; Modi, S.
    Nature Reviews Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer
    Review

    Browne, I. M.; André, F.; Chandarlapaty, S.; Carey, L. A.; Turner, N. C.
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • ESR1 F404 mutations and acquired resistance to fulvestrant in ESR1-mutant breast cancer
    Journal Article

    Kingston, B.; Pearson, A.; Herrera-Abreu, M. T.; Sim, L. X.; Cutts, R. J.; Shah, H.; Moretti, L.; Kilburn, L. S.; Johnson, H.; Macpherson, I. R.; more...
    Cancer Discovery (2024)

    Fulltext@MSK | Save
  • Nonlobular invasive breast carcinomas with biallelic pathogenic CDH1 somatic alterations: A histologic, immunophenotypic, and genomic characterization
    Journal Article

    Derakhshan, F.; Da Cruz Paula, A.; Selenica, P.; da Silva, E. M.; Grabenstetter, A.; Jalali, S.; Gazzo, A. M.; Dopeso, H.; Marra, A.; Brown, D. N.; more...
    Modern Pathology (2024)

    Fulltext@MSK | Save
  • Somatic estrogen receptor α mutations that induce dimerization promote receptor activity and breast cancer proliferation
    Journal Article

    Irani, S.; Tan, W.; Li, Q.; Toy, W.; Jones, C.; Gadiya, M.; Marra, A.; Katzenellenbogen, J. A.; Carlson, K. E.; Katzenellenbogen, B. S.; more...
    Journal of Clinical Investigation (2024)

    Fulltext@MSK | Save
  • A druggable FOXA1-glucocorticoid receptor transcriptional axis drives tumor growth in a subset of non-small cell lung cancer
    Journal Article

    Dorso, M.; Patel, P. T.; Pankov, A.; Boyer, J. A.; Soni, R. K.; Del Priore, I. S.; Hayatt, O.; Kulick, A.; Hagen, C. J.; de Stanchina, E.; more...
    Cancer Research Communications (2023)

    Fulltext@MSK | Save
  • Novel therapeutic opportunities in metaplastic breast cancer
    Meeting Abstract

    Pareja, F.; Gazzo, A.; Dopeso, H.; Brown, D.; Selenica, P.; Zhu, Y.; Blanco Heredia, J.; Gusain, L.; Pei, X.; Marra, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • APOBEC mutagenesis and macrophage infiltration in cancer
    Meeting Abstract

    Gazzo, A.; Marra, A.; Zhu, Y.; Gupta, A.; Selenica, P.; Pei, X.; Weigelt, B.; Pareja, F.; Riaz, N.; Reis, J. S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Pan-cancer assessment of the impact of intronic variants on cancer development and progression
    Meeting Abstract

    Safonov, A.; Mehine, M.; Ceyhan-Birsoy, O.; Brown, D.; Bandlamudi, C.; Forbes, A.; Gazzo, A.; Selenica, P.; Shen, R.; Khurana, E.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Prognostic and predictive impact of estrogen/progesterone receptor (ER/PR), and Ki-67 expression: An exploratory analysis from the monarchE trial in patients with high-risk, HR+, HER2-, early breast cancer (EBC)
    Meeting Abstract

    Goetz, M. P.; Turner, N.; Sasano, H.; Arteaga, C.; Chandarlapaty, S.; Loi, S.; Reis-Filho, J. S.; Kreipe, H.; Harbeck, N.; Fasching, P.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save